Healthcare
Targeted Medical Pharma, Inc.(TRGM)
Live Price
Offline$0.00001
+0.00% today
1Y Change
-90.00%
Window
Jun 20, 2025 โ Jun 5, 2026
- Market Cap
- โ
- Revenue Growth
- -26.0%
- EPS Growth
- +26.7%
- Dividend Yield
- 0.0%
Coverage: 242 bars ยท Jun 20, 2025 โ Jun 5, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Targeted Medical Pharma, Inc. (TRGM) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and down 90.0% across the available one-year price window (Jun 20, 2025 โ Jun 5, 2026). Baseline metrics include revenue growth of -26.0%, EPS growth of +26.7%, a dividend yield of 0.0%. What stands out right now is revenue -26.0%, EPS +26.7%, free cash flow -263.9% with operating margin -38.6% and ROIC 26.6%. Valuation is more restrained than many high-expectation growth names at price/sales 0.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines TRGM price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-26.0% vs +7.6% peer median
Operating Margin
Below sector median
-38.6% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2015 was reported on Nov 13, 2015, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -26.0% and EPS is at +26.7%, with operating margin around -38.6%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2015 Nov 13, 2015 | โ | +0.0% | +0.0% | +0.0% |
2015 Aug 14, 2015 | โ | +0.0% | +0.0% | +0.0% |
2015 May 15, 2015 | โ | +0.0% | +0.0% | +0.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TRGM
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
TRGM Max Drawdown
-90.00%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for TRGM and SPY.
Company Overview
Targeted Medical Pharma, Inc.
Other OTC
Targeted Medical Pharma, Inc., a specialty pharmaceutical company, doing business as Physician Therapeutics, develops and commercializes amino acid based medications to physicians, pharmacies, and patients in the United States. It offers a line of patented amino acid based medical food products, dietary supplements, and generic drugs primarily for the treatment of metabolic syndrome/obesity; sleep disorders associated with anxiety; hypertension; viral infections; cognitive disorders/fatigue; sleep disorders associated with depression, fibromyalgia, and PTSD; pain disorders and inflammatory conditions/fibromyalgia; osteoarthritis and joint disorders; and peripheral neuropathy. The company also provides a proprietary billing process and supporting software (PDRx) that facilitates physician dispensing; provides inventory control; and assists regulatory reporting. In addition, it offers billing and collection services relating to its products on behalf of dispensing physician clients to private insurance and workers' compensation insurance. Targeted Medical Pharma, Inc. distributes its products through a network of distributors and an internal sales force that sells products directly to dispensing physician clients. The company was formerly known as Targeted Medical Foods and changed its name to Targeted Medical Pharma, Inc. in 2006. Targeted Medical Pharma, Inc. was founded in 1996 and is headquartered in Los Angeles, California.
- Leadership
- Kim Giffoni
- IPO Date
- Nov 2, 2012
- Employees
- 30
- Street Address
- 2980 Beverly Glen Circle
- Mailing
- Los Angeles, CA, 90077
- Region
- Los Angeles, CA, US
- Reporting Currency
- USD
- Investor Line
- 310-474-9809
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 0.0
- Price/Book
- โ
Growth
- Revenue
- -26.0%
- EPS
- +26.7%
- Free Cash Flow
- -263.9%
Profitability
- Gross Margin
- 60.2%
- Operating Margin
- -38.6%
- Net Margin
- -57.9%
- ROE
- 26.6%
- ROIC
- 26.6%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.06
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.